CS224925B1 - The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate - Google Patents

The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate Download PDF

Info

Publication number
CS224925B1
CS224925B1 CS377582A CS377582A CS224925B1 CS 224925 B1 CS224925 B1 CS 224925B1 CS 377582 A CS377582 A CS 377582A CS 377582 A CS377582 A CS 377582A CS 224925 B1 CS224925 B1 CS 224925B1
Authority
CS
Czechoslovakia
Prior art keywords
hydroxy
dihydrodibenzo
thiepine
dimethylaminepropylidene
naphtoate
Prior art date
Application number
CS377582A
Other languages
Czech (cs)
Inventor
Miroslav Ing Csc Rajsner
Miroslav Dr Ing Drsc Protiva
Original Assignee
Rajsner Miroslav
Protiva Miroslav
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rajsner Miroslav, Protiva Miroslav filed Critical Rajsner Miroslav
Priority to CS377582A priority Critical patent/CS224925B1/en
Publication of CS224925B1 publication Critical patent/CS224925B1/en

Links

Landscapes

  • Steroid Compounds (AREA)

Description

Látka vzorce I je novou solí base E-11-(3-dimethylaminopropyl.iden)-6,11-dihydrodibenzoJb,eJthiepinu, známého pod generickými názvy prothiaden, dothiepin, regp. dosulepin. Soli této base se vyznačují vynikající antidepresivní účinností, při čemž hydrochlorid je v široké míře používán v therapeutické praxi (Metyšová J., Metyš J., Votava Z.: Arzneim.-Porsch. JJ, 1039, 1963:The compound of formula (I) is a new base salt of E-11- (3-dimethylaminopropylidene) -6,11-dihydrodibenzo [b], thiepine, known under the generic names hindered, dothiepine, regp. dosulepin. Salts of this base are distinguished by excellent antidepressant activity, the hydrochloride being widely used in therapeutic practice (Metyšová J., Metyš J., Votava Z .: Arzneim.-Porsch. JJ, 1039, 1963:

Rees J.A., Marsh B.D.: 9th Congr. CINP, Paříž, červenec. 1974» J· Pharmacol. Paris J, Suppl. 2, 84, 1974; Int.Pharmacopsychiat.Rees, J.A., Marsh B.D .: 9th Congr. CINP, PARIS, JULY. 1974 J Pharmacol. Paris J Suppl. 2, 84 (1974); Int.Pharmacopsychiat.

chloridu je jeho hořkáva 1cchloride is its bitter 1c

10, 54, 1975). Jistou nevýhodou ve vodě výborně rozpustného hydrohokálně anestetické působení při styku s ústní sliznici·10, 54, 1975). A certain disadvantage of the water-soluble hydro-local anesthetic action in contact with the oral mucosa

Nyní bylo zjištěno, že tyto nepříznivé vlastnosti nemá sůl jmenované base s kyselinou 4,4*-methylenbis(3-hydroxy-2-naftoovou), která je známa též jako kyselina pamoová nebo embonová (viz The Merck Index, 9. vyd., str. 908,· 1976). Tato sůl, která je tvoře224 925 na dvěma molekulami base a jednou molekulou kyseliny je ve vodě minimálně rozpustná, je prakticky bez chuti a nepůsobí místní znecitlivění. Při tom je výborně resorbována ze zažívacího traktu a tudíž vhodná k přípravě lékových forem prothiadenu pro orální použití.It has now been found that the salt of the said base with 4,4 ' -methylenebis (3-hydroxy-2-naphthoic acid), also known as pamoic or embonic acid, does not have these adverse properties (see The Merck Index, 9th ed., p. 908, 1976). This salt, which is 224 925 on two base molecules and one acid molecule is minimally soluble in water, is virtually tasteless and does not cause local anesthesia. In doing so, it is excellently absorbed from the gastrointestinal tract and is therefore suitable for the preparation of dosage forms of prothiadene for oral use.

Sůl vzorce I lze v principu připravit neutralisací base kyselinou. Vzhledem k tomu, že však jsou obě tyto látky nerozpustné ve vodě a produkt , tj. výsledná sůl, je rovněž nerozpustná, představuje přímá neutralisace určitý technický problém. Z toho důvodu je lépe použít podvojné reakce předem připraveného roztoku sodné soli kyseliny 4,4'-methylenbis(3-hydroxy-2-naftoové) s vodným roztokem hydrochloridu E-11-(3-dimethylaminopropyliden)-6,11-dihydrodibenzo|b,e|thiepinu. Žádaná sůl vzorce I se vyloučí jako mikrokrystalická sraženina, která se odsaje, promyje vodou a vysuší. Podle analysy má uvedené složeni.The salt of formula I can in principle be prepared by neutralizing the base with an acid. However, since both are insoluble in water and the product, i.e. the resulting salt, is also insoluble, direct neutralization is a technical problem. For this reason, it is preferable to use the double reactions of a previously prepared solution of sodium 4,4'-methylenebis (3-hydroxy-2-naphthoic acid) with an aqueous solution of E-11- (3-dimethylaminopropylidene) -6,11-dihydrodibenzo [b] hydrochloride. , e | thiepine. The desired salt of formula (I) is precipitated as a microcrystalline precipitate which is filtered off with suction, washed with water and dried. According to analysis, it has said composition.

Příprava látky vzorce I se tedy provede takto: Mícháním rozto-ku 1,6 g hydroxidu sodného ve 120 ml se 7,8 g kyseliny 4,4*-methylenbis(3-hydroxy-2-naftoové) se připraví roztok sodné soli. Zfiltruje se a filtrát se za prudkého míchání zvolna přidá k roztoku 13,2 g hydrochloridu E-1.1-(3~dimethylaminopropyliden)-6,11-dihydrodibenzo{b,ejthiepinu (Rajšner M., Protiva M.: Česk.Parm. 11. 404, 1962; Rajšner M., Svátek E., Metyšová J., Protiva M.: Collect.Czech.Chem.Coramun. 34. 1963, 1969). Vyloučená sůl vzorce I se po 30 min stání odsaje, promyje se vodou a vysuší ve vakuu. Získá se 15,0 g (76 %) monohydrátu soli I obsahující na 1 molekulu kyseliny 2 molekuly base. Produkt taje při 170 °C, při čemž počíná jihnout od 128 °C.Thus, the preparation of the compound of formula (I) is carried out as follows: A solution of sodium salt is prepared by mixing a solution of 1.6 g of sodium hydroxide in 120 ml with 7.8 g of 4,4'-methylenebis (3-hydroxy-2-naphthoic acid). It is filtered and the filtrate is slowly added to a solution of 13.2 g of E-1,1- (3-dimethylaminopropylidene) -6,11-dihydrodibenzo {b, ejthiepine hydrochloride (Rajšner M., Protiva M .: Czech Pharm. 11) under vigorous stirring. 404, 1962; Rajsner M., Sveta E., Metasova J., Protiva M .: Collect.Czech.Chem.Coramun. 34, 1963, 1969). The precipitated salt of formula I is filtered off with suction after standing for 30 minutes, washed with water and dried in vacuo. 15.0 g (76%) of the monohydrate salt I is obtained containing 2 base molecules per molecule of acid. The product melts at 170 ° C, starting to start from 128 ° C.

Claims (1)

P, RED MET VYNÁLEZUP, RED MET OF THE INVENTION 224 92S224 92S E-11-(3-Dimethylaminopropyliden)-6t1l-dihydrodibenzo E.Uthiepin^4,4 *-methylen'ois(3-hydroxy-2-naftoátý] vzorce IE-11- (3-dimethylaminopropylidene) -6 t 1 l-dihydro-4,4 E.Uthiepin -methylen'ois (3-hydroxy-2-naphthoate] Formula I Cena: 2,40 KčsPrice: 2,40 Kčs
CS377582A 1982-05-21 1982-05-21 The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate CS224925B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS377582A CS224925B1 (en) 1982-05-21 1982-05-21 The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS377582A CS224925B1 (en) 1982-05-21 1982-05-21 The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate

Publications (1)

Publication Number Publication Date
CS224925B1 true CS224925B1 (en) 1984-02-13

Family

ID=5378810

Family Applications (1)

Application Number Title Priority Date Filing Date
CS377582A CS224925B1 (en) 1982-05-21 1982-05-21 The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate

Country Status (1)

Country Link
CS (1) CS224925B1 (en)

Similar Documents

Publication Publication Date Title
JP6726964B2 (en) Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal tract diseases
EP0171372B1 (en) Sulphenamides, processes for their preparation and their use in the manufacture of pharmaceutical preparations
US6936627B2 (en) Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
DK172690B1 (en) Analogous process for the preparation of salts of sulfodehydroabietic acid or hydrates thereof
ITMI961821A1 (en) USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
FI61479B (en) FOERFARANDE FOER FRAMSTAELLNING AV SPASMOLYTISKA NYA D L-TYROSINDERIVAT
US9981043B2 (en) Analgesic conjugates
CA2372538A1 (en) Antitussive/antihistaminic/decongestant compositions
IL192023A (en) Heterocyclic compounds, compositions comprising them and uses thereof
KR100422276B1 (en) Morphine and diamorphine salts of anionic anesthetic analgesic agents in the form of substituted carboxylic acids, methods for their preparation, uses thereof, and formulations comprising these salts
AU3219600A (en) Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
FI92707B (en) A process for the preparation of new therapeutically useful estramustine esters
FI79836C (en) Process for the preparation of a pharmaceutically active N, N-di-n-propyl -4-hydroxy-3-methanesulfonamidophenethylamine
CS224925B1 (en) The e-11-/3-dimethylaminepropylidene/-6,11-dihydrodibenzo-/b,e/thiepine /4,4-methylen bis /3-hydroxy 2-naphtoate
EP0069380A1 (en) 11-Deoxoglycyrrhetinic acid hydrogen maleate, process for its production, and its use as a medicine
SU1047389A3 (en) Process for producing sulphur-containing derivatives of isoquinoline
US4314060A (en) Oxaalkanoate anti-ulcer compounds
WO2006105725A1 (en) A combination of luteolin and one of pt chemotherapeutics
AU623018B2 (en) Novel cyclic anthranilic acid acetic acid derivatives and process for the preparation
SU1213726A1 (en) 3-dimethylaminopropylamide benzthiazino[2,3-b] phenothiazine-6-carboxylic acid possessing antitumoral activity
US3876784A (en) A therapeutic method utilizing a choleretically active composition containing a morpholino derivative
JP2612417B2 (en) Gastrointestinal symptom improver
GB1579839A (en) Chlorophenoxybenzene derivatives
IE42609B1 (en) Sulphur- and oxygen-containing diaryl compounds
AU2004202027B2 (en) Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use